Prognostic impact of BRCA mutation on metastasis-free survival in a localized/locoregional high-risk real-world prostate cancer population.

Frances A. Brito(Tempus Labs (United States)), Sara Dempster(AstraZeneca (United States)), Sajan Khosla(Queen Elizabeth Hospital Birmingham), Rebecca Song(AstraZeneca (United States)), Alan Barnicle(AstraZeneca (United Kingdom)), Jessica J. P. Shami(AstraZeneca (United Kingdom)), David Roy(UNSW Sydney), Aditya Rajan(AstraZeneca (United States)), Jessica Dow(Tempus Labs (United States)), Jimmy L. Zhao(California Institute of Technology)
Journal of Clinical Oncology
June 1, 2024
Cited by 0


Related Papers